These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 32135178)

  • 1. Inhibition of PU.1 ameliorates metabolic dysfunction and non-alcoholic steatohepatitis.
    Liu Q; Yu J; Wang L; Tang Y; Zhou Q; Ji S; Wang Y; Santos L; Haeusler RA; Que J; Rajbhandari P; Lei X; Valenti L; Pajvani UB; Qin J; Qiang L
    J Hepatol; 2020 Aug; 73(2):361-370. PubMed ID: 32135178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD44 is a key player in non-alcoholic steatohepatitis.
    Patouraux S; Rousseau D; Bonnafous S; Lebeaupin C; Luci C; Canivet CM; Schneck AS; Bertola A; Saint-Paul MC; Iannelli A; Gugenheim J; Anty R; Tran A; Bailly-Maitre B; Gual P
    J Hepatol; 2017 Aug; 67(2):328-338. PubMed ID: 28323124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.
    Tølbøl KS; Kristiansen MN; Hansen HH; Veidal SS; Rigbolt KT; Gillum MP; Jelsing J; Vrang N; Feigh M
    World J Gastroenterol; 2018 Jan; 24(2):179-194. PubMed ID: 29375204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Empagliflozin Improves Metabolic and Hepatic Outcomes in a Non-Diabetic Obese Biopsy-Proven Mouse Model of Advanced NASH.
    Perakakis N; Chrysafi P; Feigh M; Veidal SS; Mantzoros CS
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34199317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adipocyte PU.1 knockout promotes insulin sensitivity in HFD-fed obese mice.
    Lackey DE; Reis FCG; Isaac R; Zapata RC; El Ouarrat D; Lee YS; Bandyopadhyay G; Ofrecio JM; Oh DY; Osborn O
    Sci Rep; 2019 Oct; 9(1):14779. PubMed ID: 31611602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor necrosis factor receptor-associated factor 5 (Traf5) acts as an essential negative regulator of hepatic steatosis.
    Gao L; Wang PX; Zhang Y; Yu CJ; Ji Y; Wang X; Zhang P; Jiang X; Jin H; Huang Z; Zhang ZR; Li H
    J Hepatol; 2016 Jul; 65(1):125-136. PubMed ID: 27032381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of Hepatocellular Fatty Acid Uptake in Mouse Models of Fatty Liver Disease with and without Functional Leptin Signaling: Roles of NfKB and SREBP-1C and the Effects of Spexin.
    Ge JF; Walewski JL; Anglade D; Berk PD
    Semin Liver Dis; 2016 Sep; 36(4):360-372. PubMed ID: 27997977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activating transcription factor 3 is a target molecule linking hepatic steatosis to impaired glucose homeostasis.
    Kim JY; Park KJ; Hwang JY; Kim GH; Lee D; Lee YJ; Song EH; Yoo MG; Kim BJ; Suh YH; Roh GS; Gao B; Kim W; Kim WH
    J Hepatol; 2017 Aug; 67(2):349-359. PubMed ID: 28365312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatocyte Kctd17 Inhibition Ameliorates Glucose Intolerance and Hepatic Steatosis Caused by Obesity-induced Chrebp Stabilization.
    Oh AR; Jeong Y; Yu J; Minh Tam DT; Kang JK; Jung YH; Im SS; Lee SB; Ryu D; Pajvani UB; Kim K
    Gastroenterology; 2023 Mar; 164(3):439-453. PubMed ID: 36402191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human translatability of the GAN diet-induced obese mouse model of non-alcoholic steatohepatitis.
    Hansen HH; Ægidius HM; Oró D; Evers SS; Heebøll S; Eriksen PL; Thomsen KL; Bengtsson A; Veidal SS; Feigh M; Suppli MP; Knop FK; Grønbæk H; Miranda D; Trevaskis JL; Vrang N; Jelsing J; Rigbolt KTG
    BMC Gastroenterol; 2020 Jul; 20(1):210. PubMed ID: 32631250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor necrosis factor alpha receptor 1 deficiency in hepatocytes does not protect from non-alcoholic steatohepatitis, but attenuates insulin resistance in mice.
    Bluemel S; Wang Y; Lee S; Schnabl B
    World J Gastroenterol; 2020 Sep; 26(33):4933-4944. PubMed ID: 32952340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pu-erh tea extract ameliorates high-fat diet-induced nonalcoholic steatohepatitis and insulin resistance by modulating hepatic IL-6/STAT3 signaling in mice.
    Cai X; Fang C; Hayashi S; Hao S; Zhao M; Tsutsui H; Nishiguchi S; Sheng J
    J Gastroenterol; 2016 Aug; 51(8):819-29. PubMed ID: 26794005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic Ablation of STE20-Type Kinase MST4 Does Not Alleviate Diet-Induced MASLD Susceptibility in Mice.
    Caputo M; Andersson E; Xia Y; Hou W; Cansby E; Erikson M; Lind DE; Hallberg B; Amrutkar M; Mahlapuu M
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38397122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Degradation of PHLPP2 by KCTD17, via a Glucagon-Dependent Pathway, Promotes Hepatic Steatosis.
    Kim K; Ryu D; Dongiovanni P; Ozcan L; Nayak S; Ueberheide B; Valenti L; Auwerx J; Pajvani UB
    Gastroenterology; 2017 Dec; 153(6):1568-1580.e10. PubMed ID: 28859855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatocyte-specific activity of TSC22D4 triggers progressive NAFLD by impairing mitochondrial function.
    Wolff G; Sakurai M; Mhamane A; Troullinaki M; Maida A; Deligiannis IK; Yin K; Weber P; Morgenstern J; Wieder A; Kwon Y; Sekar R; Zeigerer A; Roden M; Blüher M; Volk N; Poth T; Hackert T; Wiedmann L; De Angelis Rigotti F; Rodriguez-Vita J; Fischer A; Mukthavaram R; Limphong P; Tachikawa K; Karmali P; Payne J; Chivukula P; Ekim-Üstünel B; Martinez-Jimenez CP; Szendrödi J; Nawroth P; Herzig S
    Mol Metab; 2022 Jun; 60():101487. PubMed ID: 35378329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N-substituted phenylbenzamides of the niclosamide chemotype attenuate obesity related changes in high fat diet fed mice.
    Bhagat HA; Compton SA; Musso DL; Laudeman CP; Jackson KMP; Yi NY; Nierobisz LS; Forsberg L; Brenman JE; Sexton JZ
    PLoS One; 2018; 13(10):e0204605. PubMed ID: 30359371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD36 palmitoylation disrupts free fatty acid metabolism and promotes tissue inflammation in non-alcoholic steatohepatitis.
    Zhao L; Zhang C; Luo X; Wang P; Zhou W; Zhong S; Xie Y; Jiang Y; Yang P; Tang R; Pan Q; Hall AR; Luong TV; Fan J; Varghese Z; Moorhead JF; Pinzani M; Chen Y; Ruan XZ
    J Hepatol; 2018 Sep; 69(3):705-717. PubMed ID: 29705240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TLR9 is up-regulated in human and murine NASH: pivotal role in inflammatory recruitment and cell survival.
    Mridha AR; Haczeyni F; Yeh MM; Haigh WG; Ioannou GN; Barn V; Ajamieh H; Adams L; Hamdorf JM; Teoh NC; Farrell GC
    Clin Sci (Lond); 2017 Aug; 131(16):2145-2159. PubMed ID: 28687713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liraglutide improves hepatic steatosis and metabolic dysfunctions in a 3-week dietary mouse model of nonalcoholic steatohepatitis.
    Duparc T; Briand F; Trenteseaux C; Merian J; Combes G; Najib S; Sulpice T; Martinez LO
    Am J Physiol Gastrointest Liver Physiol; 2019 Oct; 317(4):G508-G517. PubMed ID: 31460789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myeloid-specific IRE1alpha deletion reduces tumour development in a diabetic, non-alcoholic steatohepatitis-induced hepatocellular carcinoma mouse model.
    Van Campenhout S; Tilleman L; Lefere S; Vandierendonck A; Raevens S; Verhelst X; Geerts A; Van Nieuwerburgh F; Van Vlierberghe H; Devisscher L
    Metabolism; 2020 Jun; 107():154220. PubMed ID: 32243868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.